Cancer Immunotherapy Market to Surpass USD 214.7 billion by 2030, Growing at 8.12% CAGR

MarkNtel Advisors, a leading market research and consulting firm, has announced the release of its latest study titled Cancer Immunotherapy Market Research Report: Forecast (2025–2030). This report provides a detailed assessment of the Cancer Immunotherapy, covering its evolving dynamics, emerging trends, key growth drivers, major challenges, and competitive landscape.

Designed to guide investors, stakeholders, and business leaders, the research aims to deliver valuable insights for strategic planning, risk assessment, and investment decision-making in the years ahead.

Cancer Immunotherapy Market Timeline Overview

• Historical Years: 2020–23
• Base Year: 2024
• Forecast Years: 2025–2030

This helps businesses identify emerging opportunities, assess market risks, and develop data-driven strategies for long-term success.

Download a FREE PDF Sample of the Report: - https://www.marknteladvisors.com/query/request-sample/global-cancer-immunotherapy-market.html   (Discover the market potential, platform-specific insights, and key industry trends.)

Cancer Immunotherapy Market Outlook

The Global Cancer Immunotherapy Market size was valued at around USD 134.4 billion in 2024 and is projected to reach USD 214.7 billion by 2030. Along with this, the market is estimated to grow at a CAGR of around 8.12% during the forecast period, i.e., 2025-30.. The market is projected to experience significant growth due to several factors. One of the primary drivers is the increasing adoption of targeted therapy over traditional therapy, which has led to the emergence of biosimilars and increased demand for monoclonal antibodies (mAbs). The high prevalence of cancer also contributes to the rising inclination for such therapy, as immunotherapy drugs alter or boost the body's natural immune response to fight cancer. In conjugation, different immunotherapies, including CAR T-cell therapy, cancer vaccines, and immunomodulators, can be combined with other cancer treatments to achieve the best outcomes.

In case you missed it, we are currently revising our reports. Click on the below to get the latest research data with forecast for years 2026 to 2032, including market size, industry trends, and competitive analysis. It wouldn’t take long for the team to deliver the most recent version of the report.

Cancer Immunotherapy Market Drivers:

Increasing Frequency of Approvals Received by Novel Immunotherapies - Increasing acceptance of novel immunotherapies is expected to bode well for market expansion in the coming years. For instance, The U.S. FDA authorized a number of anti-PD-1/L1 antibodies between 2020 and 2022 for the treatment of NSCLC, renal cell carcinoma, melanoma, breast, prostate, and other malignancies. These antibodies include nivolumab, atezolizumab, avelumab, dostarlimab, and others. Therefore, the increased approval of immunotherapeutic drugs has fueled market development in the past few years.

View Full Report (All Data, In One Place): - https://www.marknteladvisors.com/research-library/global-cancer-immunotherapy-market.html  (Explore in-depth analyses, technological trends, and investment patterns.)

Cancer Immunotherapy Market Trends:

Key Trend: A Paradigm Shift from Conventional Chemotherapies to Immunotherapies Owing to Higher Efficacy of Newer Therapies

Increased research and development efforts in cancer immunotherapy have resulted in the development of advanced versions with better therapeutic efficacies. In fact, immuno-oncology has exhibited encouraging results, including improved survival and reduced toxicity. Besides, immunotherapies under research are anticipated to provide more treatment options and superior results than current medications. This has resulted in a paradigm shift from conventional chemotherapies to immunotherapies, consequently pushing the market forward. Furthermore, launching emerging medication classes targeting multiple myeloma receptors, such as monoclonal antibodies and histone deacetylase (HDAC) inhibitors, is anticipated to boost the ancer immunotherapy market growth worldwide.

Cancer Immunotherapy Market Segmentation

The study categorizes the Cancer Immunotherapy Market into various segments and sub-segments, each analyzed for its size, growth potential, and contribution to the overall industry.

By Product Type

• Monoclonal Antibodies
• Immunomodulators
• Oncolytic Viral Therapies and Cancer Vaccines
• Checkpoint Inhibitors
• Others

By Cancer Type

• Lung Cancer
• Prostate Cancer
• Breast Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Head and Neck Cancer
• Melanoma
• Colorectal Cancer

By Mechanism of Actions

• Active Immunotherapy
• Passive Immunotherapy

By End Users

• Hospitals
• Cancer Research Centers
• Clinics

Geographical Analysis

The report presents detailed insights into the market’s geographical expansion, highlighting key trends and opportunities across the following geographies:

By Region

• North America
• Latin America
• Europe
• Middle East and Africa
• Asia-Pacific.

Talk to Our Industry Analyst:  - https://www.marknteladvisors.com/query/request-sample/global-cancer-immunotherapy-market.html  Get personalized insights into company strategies and regional market dynamics.)

Leading Companies in Cancer Immunotherapy Market Worldwide: Players, Analysis & Future Outlook

Amgen Inc., Astrazeneca, Bayer AG, Bristol-Myers Squibb, ELI Lilly and Company, Janssen Services LLC, Johnson and Johnson), Merck, Novartis, Pfizer, and F. Hoffmann-La Roche AG are the top players in the market.

Key Highlights of the Report

• Comprehensive Market Overview: In-depth analysis of market size, share, and forecasts from 2025 to 2030.
• Growth Drivers & Challenges: Clear insights into factors feeling or restraining market expansion.
• Investment & Regulatory Insights: Evaluation of key policies, funding trends, and collaborations influencing industry performance.
• Competitive Landscape: Detailed profiles of leading companies, including product portfolios, business strategies, financials, and recent developments such as mergers & acquisitions.

Analytical Tools: Application of SWOT Analysis, PESTEL Analysis, and Porter’s Five Forces Model to assess competition and external influences

Browse through our flexible pricing plans and choose the package that best fits your business needs whether you require a single-user license, corporate access, or customized insights. Once you select the plan that suits your requirements, you can purchase and instantly access the full report online – https://www.marknteladvisors.com/pricing/global-cancer-immunotherapy-market.html   

Frequently Asked Questions (FAQ)

1. What is the projected growth rate of the Cancer Immunotherapy Market?
   2. What are the major factors driving this market’s growth?
   3. Which regions are expected to lead the Cancer Immunotherapy Market?
   4. Who are the prominent players in the Cancer Immunotherapy Market?
   5. How is the competition structured in this market?
   6. How can I access the full report?

About Us

MarkNtel Advisors is a globally recognized market research and consulting firm delivering intelligence across the healthcare industry, spanning pharmaceuticals, medical devices, healthcare IT, and biotechnology. Our analysts combine domain expertise with innovation tracking to help healthcare organizations improve efficiency and patient outcomes. Through Consulting Services, we assist clients in interpreting insights, designing go-to-market strategies, and adapting to regulatory changes, fostering sustainable growth in the evolving global healthcare ecosystem.

Contact Us:
MarkNtel Advisors
Sector 63, Noida, Uttar Pradesh-201301, India
Contact No: +91 87199 99009
Email: sales@marknteladvisors.com
Website: https://www.marknteladvisors.com